J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible

Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.

Johnson_and_Johnson
J&J plans to split off its consumer health unit as a separate public company

Johnson & Johnson’s announcement that it will spin off one of the industry’s oldest and largest consumer health businesses to focus on its biopharmaceutical and medical device operations came as a surprise, but J&J execs explained that the pandemic has made it recognize key differences between the divisions. And the decision follows similar efforts to slim down and tighten focus at other big pharmas such as Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc. and Sanofi.

J&J outlined a plan on 12 November to split off the health care conglomerate’s consumer health unit into a separate,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.